Authors
Catherine P Benziger, Amanda Stebbins, Lisa M Wruck, Mark B Effron, Guillaume Marquis-Gravel, Peter M Farrehi, Saket Girotra, Kamal Gupta, Sunil Kripalani, Daniel Munoz, Tamar S Polonsky, Amber Sharlow, Jeffrey Whittle, Robert A Harrington, Russell L Rothman, Adrian F Hernandez, W Schuyler Jones
Publication date
2024/7/10
Journal
JAMA cardiology
Description
Importance
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality in the US. Although aspirin is recommended for secondary prevention of ASCVD, there was no difference in safety and effectiveness of aspirin dosed daily at 81 mg or 325 mg in the ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness) randomized clinical trial. However, it is unknown whether differences by sex exist in the safety and effectiveness of the different aspirin doses.
Objective
To evaluate sex-specific differences in the safety and effectiveness of 2 aspirin doses in the ADAPTAPLE trial.
Design, Setting, and Participants
The ADAPTABLE study was an open-label, pragmatic, randomized clinical trial that randomly assigned participants with chronic, stable ASCVD to 81 mg vs 325 mg of aspirin daily. Using Cox proportional-hazard models, male and …
Scholar articles
CP Benziger, A Stebbins, LM Wruck, MB Effron… - JAMA cardiology, 2024